Combining treatment for chronic hepatitis C with opioid agonist therapy is an effective microelimination strategy for people who inject drugs with high risk of non-adherence to direct-acting antiviral therapy

• Asıl Yazarlar: M. Schwarz (Yazar), C. Schwarz (Yazar), A. Schütz (Yazar), C. Schwanke (Yazar), E. Krabb (Yazar), R. Schubert (Yazar), S.-T. Liebich (Yazar), D. Bauer (Yazar), L. Burghart (Yazar), L. Brinkmann (Yazar), E. Gutic (Yazar), T. Reiberger (Yazar), H. Haltmayer (Yazar), M. Gschwantler (Yazar)
• Materyal Türü: Kitap
• Baskı/Yayın Bilgisi: Elsevier, 2023-03-01T00:00:00Z.
• Konular: article
• Online Erişim: Connect to this object online.

Background & aims: Despite effective direct-acting antivirals (DAAs), hepatitis C virus (HCV) prevalence is high among people who inject drugs (PWIDs) and non-adherence to therapy remains a major obstacle towards HCV elimination in this subpopulation. To overcome this issue, we have combined ong...